All In Biotech

Drug Trial Radar · NCT06292013

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 17,300 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

17,300

Planned (sponsor's estimate)

Start

Mar 5, 2024

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.

Conditions

  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Elevated Lp(a)

Interventions

  • Lepodisiran SodiumDrug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite EndpointTime frame: Baseline up to End of Study (About 4.5 Years)

Locations

928 sites in 28 countries. Site status is shown where the registry gives one.

  • Birmingham Clinical Research

    Birmingham, Alabama

  • Alliance for Multispecialty Research, LLC

    Daphne, Alabama

  • SEC Clinical Research

    Dothan, Alabama

  • Alliance for Multispecialty Research, LLC

    Mobile, Alabama

  • Mobile Heart Specialists

    Mobile, Alabama

  • Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC

    Gilbert, Arizona

  • Mercy Gilbert Medical Center

    Gilbert, Arizona

  • Sun City Clinical Research

    Glendale, Arizona

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Helios Clinical Research - Phoenix

    Phoenix, Arizona

  • Absolute Clinical Research

    Phoenix, Arizona

  • Clinical Research Institute of Arizona (CRI) - Sun City West

    Sun City West, Arizona

  • Pima Heart

    Tucson, Arizona

  • Synexus Clinical Research US, Inc./Orange Grove Family Practice

    Tucson, Arizona

  • Eclipse Clinical Research

    Tucson, Arizona

  • Cardiology and Medicine Clinic

    Little Rock, Arkansas

  • National Heart Institute

    Beverly Hills, California

  • Valley Clinical Trials, Inc.

    Covina, California

  • Neighborhood Healthcare Institute of Health

    Escondido, California

  • HB Clinical Trials - Fountain Valley

    Fountain Valley, California

  • Care Access - Huntington Beach

    Huntington Beach, California

  • 310 Clinical Research

    Inglewood, California

  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)

    La Jolla, California

  • Scripps Whittier Diabetes Institute

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • MemorialCare Health System - Long Beach Medical Center

    Long Beach, California

  • Ark Clinical Research

    Long Beach, California

  • Keck School of Medicine of USC

    Los Angeles, California

  • Cardiovascular Research Foundation of Southern California

    Los Angeles, California

  • Valley Clinical Trials, LLC dba Flourish Research

    Northridge, California

  • Desert Oasis Healthcare Medical Group

    Palm Springs, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Care Access - Santa Clarita

    Santa Clarita, California

  • Stanford University Medical Center

    Stanford, California

  • Olive View-UCLA Medical Center

    Sylmar, California

  • Care Access - Thousand Oaks

    Thousand Oaks, California

  • Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.

    Toluca Lake, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • UCLA South Bay Endocrinology

    Torrance, California

  • InvivoCure

    Van Nuys, California

Showing 40 of 928 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.